About: Zoledronic Acid     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Zoledronic Acid
rdfs:subClassOf
Has_Salt_Form
Concept_In_Subset
Semantic_Type
  • Pharmacologic Substance
  • Organophosphorus Compound
Preferred_Name
  • Zoledronic Acid
NSC_Code
  • 721517
UMLS_CUI
  • C0257685
CAS_Registry
  • 165800-06-6
Accepted_Therapeutic_Use_For
  • Hypercalcemia of malignancy; Multiple myeloma and metastatic bone lesions from solid tumors; Paget's disease
In_Clinical_Trial_For
  • Cancer related bone lesions; Osteoporosis; Osteogenesis Imperfecta; Paget's Disease of Bone; Prostate Cancer; Bone Metastases.
FDA_UNII_Code
  • 6XC1PAD3KF
Contributing_Source
  • FDA
ALT_DEFINITION
  • A drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate.NCI-GLOSS
PDQ_Open_Trial_Search_ID
  • 42507
PDQ_Closed_Trial_Search_ID
  • 42507
Chemical_Formula
  • C5H10N2O7P2.H2O
Legacy_Concept_Name
  • Zoledronate
FULL_SYN
  • ZOLEDRONIC ACIDPTFDA6XC1PAD3KF
  • [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic AcidPTDCP50451
  • NDC-ZoledronateSYNCI
  • Zoledronic AcidPTNCI
  • ZometaPTNCI-GLOSSCDR0000487473
  • ZometaBRNCI
  • ZOL 446CNNCI
  • ReclastBRNCI
  • Zoledronic AcidPTNCI-GLOSSCDR0000045500
  • zoledronic acidPTNCI-GLOSSCDR0000487470
  • CGP 42446CNNCI
  • CGP42446ACNNCI
  • [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic AcidSNNCI
DEFINITION
  • A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.NCI
code
  • C1699
sameAs
http://linked.open...y/mesh/hasConcept
is someValuesFrom of
is Has_Free_Acid_Or_Base_Form of
is sameAs of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 112 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software